Adalimumab
Contents
Description
Adalimumab is a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. It is approved for the treatment of polyarticular juvenile idiopathic arthritis in patients 2 years and older who have had an inadequate response to one or more DMARDs. The drug is administered via subcutaneous injection and provides targeted immunosuppression.
Indications & Therapeutic Use
polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Adalimumab — GNH India
105 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | adalimumab |
| Brands | 1 brand available |
| Active Ingredient | adalimumab |
| Drug Class | polyarticular juvenile idiopathic arthritis |
| Manufacturer | AbbVie |
| Dosage Forms | subcutaneous injection 40mg/0.8mL, 20mg/0.4mL prefilled syringe |
| Medical Code | L04AB04 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00048542 |
| Countries | 9 countries |